AstraZeneca has agreed to pay the UK government £505 million to settle a long-running and complex dispute with the tax authorities1. At the heart of the dispute is the issue of transfer pricing, an accounting method that allows companies to transfer their intangible assets to subsidiaries to lower their tax liability...
Please login to read the full article.
